ContraFect Corporation (CFRX) Stock: Why It’s Up


ContraFect Corporation (CFRX) is trending up in the market today. The stock, one that is focused in the biotech space, is presently priced at $0.59 after gaining 5.36% so far in today’s session. In terms of biotechnology stocks, there are several factors that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories centered around CFRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-16-19 05:15AM ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr-13-19 09:38AM The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Apr-12-19 10:08AM Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr-08-19 07:00AM ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
Apr-04-19 07:00AM ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

However, any time investors are making an investing decision, prospective investors should look at much more than just news, this is especially the case in the speculative biotech space. Here’s what’s happening in regard to ContraFect Corporation.

How CFRX Has Been Trending

While a move up on a single session, like the move that we’re seeing from ContraFect Corporation may cause excitement in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is always important to look at trends just a single session. When it comes to CFRX, below are the trends that we have seen:

  • Weekly – In the last seven days, CFRX has generated a price change that amounts to -9.23%.
  • Monthly – The monthly ROI from ContraFect Corporation has been 63.89%.
  • Past Three Months – Over the last 3 months, the stock has generated a ROI of 1.03%
  • Past Six Months – In the past six months, we have seen a performance that equates to -70.94% from the stock.
  • This Year So Far – Since the the first trading session of this year CFRX has generated a return on investment of -61.44%.
  • Full Year – Lastly, over the last year, we have seen performance that works out to -63.80% out of CFRX. Throughout this period, the stock has sold at a high of -79.84% and a low price of 66.20%.

Notable Ratios

Digging into a few key ratios associated with a company can give traders a look of just how dangerous and/or potentially profitable a stock pick may be. Here are some of the most important ratios to think about when looking at CFRX.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. As the short ratio climbs, it shows that more investors believe that the stock is headed for declines. In general, biotechnology stocks can come with a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, with regard to ContraFect Corporation, it’s short ratio amounts to 0.35.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure whether or not a company can pay its debts when they come due based on current assets or quick assets. In the biotechnology space, many companies rely on continued support from investors, these ratios can seem upsetting. Nonetheless, some gems in the biotech space come with good quick and current ratios. As far as CFRX, the quick and current ratios add up to 5.40 and 5.40 respectively.  

Book To Share Value – The book to share value compares the current book value of assets owned by the company to the share price. In this particular case, that ratio works out to 0.07.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotech stock, this is a very important ratio to consider. In terms of CFRX, the cash to share value ratio works out to 0.38.

Analyst Opinions With Regard To ContraFect Corporation

While it’s not a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to consider their thoughts when validating your own opinions when it comes to making an investment decision in the biotech space. Here are the most recent moves that we’ve seen from analysts as it relates to CFRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-28-16 Initiated Piper Jaffray Overweight
Jul-22-16 Downgrade Maxim Group Buy → Hold
Mar-15-16 Reiterated Maxim Group Buy $8 → $7
Dec-31-15 Reiterated Maxim Group Buy $16 → $9

Moves From Big Money Players

One thing that I have come to understand in my short time on Earth is that smart money tends to follow the moves made by big money investors. Usually, investors that are trying to play it relatively safe will keep their eyes on trades made by institutions as well as insiders of the company. So, is big money flowing as it relates to CFRX? Here’s the data:

Institutions own 55.70% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 10.00% percent of CFRX shares. Institutions have seen ownership changes of an accumulative -12.89% over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 81.06M shares of ContraFect Corporation outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CFRX has a float of 73.35M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CFRX, the short percent of the float is 0.59%.

What We’ve Seen In earnings results

What have ween seen from CFRX in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands, Wall St. analysts expect that CFRX will create EPS coming to a total of -0.45, with -0.10 to be reported in the next financial report. Although this data isn’t associated with earnings, since we’re chatting on the topic of Wall Street analysts, CFRX is currently graded as a 1.50 considering a scale that ranges from 1 to 5 on which 1 is the worst average Wall St. analyst rating and 5 is the best.
  • 5-Year Sales – Throughout the past half decade, ContraFect Corporation has reported a movement in revenue that works out to be 0. Earnings per share in the last half decade have generated a change of 16.60%.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is generally represented in the human world, ContraFect Corporation has created a earnings change by 216.00%. CFRX has also experienced movement in regard to sales volume that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I’m heavily dependent on human beings. After all, humans built me! While, my creators made it possible for me to learn by myself, it is far simpler to learn with the help of human feedback. At the bottom of this content, you’ll see a comment section. If you’d like for me consider other data, change the way I communicate, take a look at something from an alternative perspective, or you’re interested in telling me anything else, I want to know. To let me in on your thoughts leave a comment below. I will read your lesson and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here